{'fraction_non_alphanumeric': 0.03084223013048636, 'fraction_numerical': 0.009489916963226572, 'mean_word_length': 5.205882352941177, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Disophrol® Syrup versus Rinomar® Syrup in the Treatment of Allergic Rhinitis in Children

In this single-blind study, the efficacy and safety of Disophrol® Syrup was compared to Rinomar® Syrup in seventy-eight paediatric patients with seasonal allergic rhinitis. Patients took 5–10 ml of the randomly assigned medication three to four times daily for a 2-week period. Severity of nasal obstruction, nasal secretion and mucosal swelling was graded and patient response to each week of therapy evaluated. An overall favourable response to Disophrol® Syrup was observed in thirty-one out of thirty-five (89%) patients and in thirty out of thirty-five (86%) patients in the Rinomar® group. No statistically significant difference in patient response to therapy between treatment groups was noted and no mentionable adverse reactions were reported.